secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001140361-22-040018
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Q3 net loss $4.5M; Nyxol NDA on track for Q4 2022
----------------------------------------------------------

- Cash and equivalents of $13.9M as of Sept 30, 2022; runway into Q4 2023.
- Net loss of $4.5M for Q3 2022 ($0.22 per share); R&D expenses $2.8M.
- NDA submission for Nyxol (reversal of mydriasis) planned in Q4 2022.
- Topline data from ZETA-1 Phase 2b trial of APX3330 expected early 2023.
- U.S. patent for Nyxol extended into 2039; new KOLs appointed to advisory board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036122040018/0001140361-22-040018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036122040018/brhc10043741_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-040018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer